Rosuvastatin 2

DRUG2 trials

Sponsors

AstraZeneca

Conditions

Hypercholesterolaemia

Phase 3

A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholesterolaemia

Not yet recruitingNCT07619118

AstraZenecaHypercholesterolaemia

Start: 2026-09-15End: 2027-05-28Target: 200Updated: 2026-06-01

A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.

RecruitingNCT07619131

AstraZenecaHypercholesterolaemia

Start: 2026-08-12End: 2027-07-30Target: 600Updated: 2026-09-10